Sign In
Buy BIIB
$196.45
+0.490 (+0.250%)
At Close: Jun 04, 2026
Zacks Market Edge Highlights: ExxonMobil, Meta Platforms, UnitedHealth Group, Biogen and NVIDIA
11:30am, Thursday, 06'th Oct 2022 Zacks Investment Research
ExxonMobil, Meta Platforms, UnitedHealth Group, Biogen and NVIDIA are part of the Zacks Market Edge article.
Is This Stock a Buy After Soaring by 37%?
09:30am, Thursday, 06'th Oct 2022
Don't press the buy button too fast.
3 Alzheimer Stocks To Buy As The Race For A Cure Heats Up
08:56am, Thursday, 06'th Oct 2022 Investing.com
Should You Sell Your FANGMAN Stocks?
07:25pm, Wednesday, 05'th Oct 2022 Zacks Investment Research
Tracey and Kevin discuss the rocky 2022 stock market and the future of growth stocks.
Better Alzheimer's Disease Stock: Eli Lilly or Biogen?
02:00pm, Wednesday, 05'th Oct 2022 The Motley Fool
One of these stocks has significantly outperformed the other over the past year. Will that continue?
Better Alzheimer's Disease Stock: Eli Lilly or Biogen?
10:00am, Wednesday, 05'th Oct 2022
One of these stocks has significantly outperformed the other over the past year. Will that continue?
3 Revolutionary Stocks I'd Buy Right Now Without Hesitation
02:23pm, Tuesday, 04'th Oct 2022 The Motley Fool
These biotech stocks are finding game-changing therapies, and their shares are up as a result.
Biogen Shares Climb Again on Results From Alzheimer's Study
06:24pm, Monday, 03'rd Oct 2022
"Those that fail to learn from history are doomed to repeat it.” -Winston Churchill
Is Eli Lilly Stock a Buy Following This Competitor's Major Win?
02:37pm, Monday, 03'rd Oct 2022 The Motley Fool
Eli Lilly's recent jump could be short-lived.
Can AbbVie's (ABBV) New Drugs Make up for Lost Humira Sales?
01:35pm, Monday, 03'rd Oct 2022 Zacks Investment Research
AbbVie's (ABBV) new drugs, Skyrizi and Rinvoq, are faring well, bolstered by approval in new indications. They are expected to drive revenues once Humira loses U.S. exclusivity in 2023.
Can Biogen (BIIB) Navigate Multiple Challenges & Grow Again?
01:15pm, Monday, 03'rd Oct 2022 Zacks Investment Research
Most of Biogen's (BIIB) key drugs are facing declining sales. Despite these challenges, we are hopeful that potential new product launches such as lecanemab, zuranolone and additional biosimilars can
Social Security Recipients Might Actually Get to Keep Their 2023 Raise
09:05am, Sunday, 02'nd Oct 2022 The Motley Fool
2022's boost wasn't everything it was advertised to be for most seniors.
Why the Porsche IPO Generated So Much Excitement
01:47pm, Saturday, 01'st Oct 2022 The Motley Fool
Plus we look at some good news for Biogen and mortgage rate news.
What Happened This Week: Quantifying The Pain Of September, Yet Buffett Is Buying
12:25pm, Saturday, 01'st Oct 2022 Investing.com
Wall Street Breakfast: What Moved Markets
11:33am, Saturday, 01'st Oct 2022 Seeking Alpha
Listen on the go! A daily podcast of Wall Street Breakfast will be available this morning on Seeking Alpha, iTunes, Stitcher and Spotify. The major U.S.
